Comparing the 7th and 8th editions of the American Joint Committee on Cancer/Union for International Cancer Control TNM staging system for esophageal squamous cell carcinoma treated by definitive radiotherapy
- 66 Downloads
We retrospectively compared the 7th and the 8th editions of The American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) TNM classification in the cohort of survival of the patients with esophageal squamous cell carcinoma (ESCC) treated by definitive radiotherapy.
We included in this study 403 patients with ESCC who underwent radiotherapy or chemoradiotherapy, at a total radiation dose of ≥ 50 Gy with curative intent from 2000 to 2016 at Kindai University Hospital, and who had no distant metastasis (excluding supraclavicular lymph node). The same patient data set was re-staged according to both the 7th and 8th editions of AJCC/UICC TNM classification.
For the 7th edition, 5-year overall survival (OS) for stages I, II, III, and IV were 58%, 52%, 22%, and 12%, respectively, which seemed to be separable into two groups (Stages I–II and III–IV). In the 8th edition, corresponding values for stages I, II, III, and IV were 65%, 44%, 34%, and 16%, respectively, which seemed to be separated into three groups (Stage I, II–III, and IV).
The 8th edition of AJCC/UICC TNM classification is a useful predictor of OS among ESCC patients who were treated with definitive radiotherapy.
KeywordsEsophageal cancer Radiotherapy Staging system
We thank the Edanz Group (http://www.edanzediting.com/ac) for editing a draft of this manuscript.
This study was funded by JSPS KAKENHI Grant number 16K10406.
Compliance with ethical standards
The IRB of our institute approved this study (approve number: 2017-217). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent or a substitute for it was obtained from all patients included in the study.
Conflict of interest
The author Yasumasa Nishimura has received grants from Company AstraZeneca. The other authors have no conflict of interests.
- 1.Vital Statistics Japan (Ministry of Health, Labour and Welfare). https://ganjoho.jp/reg_stat/. Accessed 28 Apr 2018.